Literature DB >> 2990522

The iron-chelating agent picolinic acid enhances transferrin receptors expression in human erythroleukaemic cell lines.

U Testa, F Louache, M Titeux, P Thomopoulos, H Rochant.   

Abstract

Picolinic acid, a metal chelating molecule, was administered to human erythroleukaemic cell lines (K 562 and HEL) that were grown in serum-containing media. Picolinic acid inhibited both iron uptake and cell growth. Furthermore, picolinic acid was shown to markedly decrease the level of ferritin in the cells. In spite of the inhibition of cell growth, picolinic acid induced a marked increase in the transferrin-binding capacity of the cells. This phenomenon was due to a two-five-fold enhancement of the rate of transferrin receptor biosynthesis. Other iron-chelating compounds, capable of reducing the level of intracellular iron, also elicited a marked enhancement of the transferrin-binding capacity of the cells. However, the addition of iron, as ferric ammonium citrate, in the culture medium elicited a marked increase in the level of ferritin and a strong decrease in the transferrin-binding capacity of the cells. On the basis of these data we propose that a feed-back mechanism is involved in the regulation of transferrin receptors: when the cells accumulate iron they decrease the number of transferrin receptors in order to prevent further accumulation of iron; when no or low iron is available to the cells, the number of transferrin receptors markedly increases as a compensatory mechanism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990522     DOI: 10.1111/j.1365-2141.1985.tb07446.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron.

Authors:  R S Eisenstein; D Garcia-Mayol; W Pettingell; H N Munro
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

2.  Chelation of transferrin iron by desferrioxamine in K562 cells. The partition of iron between ferrioxamine and ferritin.

Authors:  S Roberts; A Bomford
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

Review 3.  Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment.

Authors:  G Vreugdenhil; A J Swaak
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

Review 4.  The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.

Authors:  Hamed Hosseinalizadeh; Mehrdad Mahmoodpour; Ali Akbar Samadani; Mehryar Habibi Roudkenar
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.738

Review 5.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

6.  Structural analogues of pyrroline 5-carboxylate specifically inhibit its uptake into cells.

Authors:  A J Mixson; J M Phang
Journal:  J Membr Biol       Date:  1991-05       Impact factor: 1.843

7.  Effect of intracellular iron depletion by picolinic acid on expression of the lactoferrin receptor in the human colon carcinoma cell subclone HT29-18-C1.

Authors:  T Mikogami; T Marianne; G Spik
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

8.  Synthesis and characterization of iron(II) quinaldate complexes.

Authors:  Dylan T Houghton; Nicholas W Gydesen; Navamoney Arulsamy; Mark P Mehn
Journal:  Inorg Chem       Date:  2010-02-01       Impact factor: 5.165

9.  The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.

Authors:  Anna Zinger; Carlos Barcia; Maria Trinidad Herrero; Gilles J Guillemin
Journal:  Parkinsons Dis       Date:  2011-06-03

10.  Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period.

Authors:  Bernadett Tuka; Aliz Nyári; Edina Katalin Cseh; Tamás Körtési; Dániel Veréb; Ferenc Tömösi; Gábor Kecskeméti; Tamás Janáky; János Tajti; László Vécsei
Journal:  J Headache Pain       Date:  2021-06-25       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.